Company intelligence / Profile preview

Provecs Medical

Hamburg, Hamburg, Germany

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Provecs Medical is developing ENVIRO, a patented adenoviral gene therapy platform enabling targeted delivery of up to four biologicals in one product; its lead candidate Immunalon expresses interleukin-12, interleukin-2, and CD137 ligand to modulate the tumor microenvironment by turning off tumor-mediated immune suppression and promoting T‑cell infiltration in solid tumors, including bladder cancer in partnership with Medac.

Therapeutic areas: Oncology
Modalities: Gene therapyOncolytic virus therapyVaccine
Industry: Biotech

Drug pipeline

1 asset

Immunalon

Preclinical

Partnerships

Medac Gesellschaft für klinische Spezialpräparate mbH (development partnership in urinary bladder cancer for Immunalon)

Beyond the preview

Go deeper on Provecs Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Provecs Medical.

Explore the full profile